SS
AUTL

SBI Securities’s Autolus Therapeutics AUTL Stock Holding History

SBI Securities’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86 Sell
54
-1
-2% -$2 ﹤0.01% 3541
2026
Q1 		$76 Buy
55
+5
+10% +$8 ﹤0.01% 3483
2025
Q4 		$100 Sell
50
-1
-2% -$2 ﹤0.01% 3401
2025
Q3 		$83 Buy
51
+1
+2% +$2 ﹤0.01% 3571
2025
Q2 		$114 Sell
50
-10
-17% -$17 ﹤0.01% 3495
2025
Q1 		$93 Buy
60
+10
+20% +$20 ﹤0.01% 3463
2024
Q4 		$118 Buy
+50
New +$169 ﹤0.01% 3411

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SBI Securities's AUTL Position: Q2 2026 in Review

SBI Securities reduced its Autolus Therapeutics (AUTL) stake by 1.8% in Q2 2026, selling an estimated $2 and leaving 54 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #3541.

SBI Securities first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $118 in Q4 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • SBI Securities held 54 shares of Autolus Therapeutics worth $86 as of Q2 2026.
  • SBI Securities sold 1 Autolus Therapeutics share in Q2 2026, an estimated $2.
  • Autolus Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3541 holding.
  • SBI Securities first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Autolus Therapeutics position peaked at $118 in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.